UroGen Pharma Ltd.
UroGen Pharma Ltd. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 7.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 14 concluded trials, 64% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 4, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| March 15, 2027 | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | Trial Milestone | Phase 3 |
| August 2, 2029 | A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC | Trial Milestone | Phase 1 |
Track URGN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open URGN in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.